Stowe Pharmaceuticals

Stowe Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of immunotherapeutic treatments for cancer and viral diseases. The company's lead candidate, STW-101 (also known as Z-100), is a polysaccharide-based immunomodulator derived from Mycobacterium tuberculosis that has demonstrated the ability to stimulate the immune system and promote hematopoietic recovery. STW-101 has been extensively studied in Japan and is being advanced by Stowe for the treatment of cervical cancer and radiation-induced side effects. The company aims to leverage established clinical data to bring novel supportive care and oncology treatments to the global market.